News & Events about Veracyte Inc.
Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy (ROM) associated with thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. The findings, which were...
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has ...
Ticker Report
2 months ago
Veracyte (NASDAQ:VCYT Get Rating) had its target price raised by SVB Leerink from $30.00 to $35.00 in a research report released on Thursday morning, MarketBeat Ratings reports. The firm currently has an outperform rating on the biotechnology companys stock. Other equities research ...
Business Wire
3 months ago
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the companys Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage...
Business Wire
3 months ago
Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior. The findings were derived from whole-transcriptome analyses of Veracytes extensive thyroid nodule database and were presented at the American Thyroid Association Annual Meeting, held October...